Tag Archives: AEterna Zentaris

Biogen Idec Inc. (NASDAQ:BIIB) Stops Developing dexpramipexole after Trial Failure – BIIB, PFE, CELG, ABT, BGMD, AEZS, MRK, UNH, BSX

Posted on January 3, 2013 by Geoff Noir

Biogen Idec Inc. (NASDAQ:BIIB) reported that its Phase 3 clinical trial for an ALS therapy did not match its keyobjectives, causing the biopharmaceutical company to end development of the medicine for the disease.

Shares of the company plunged 5.9% to …

Posted in Healthcare, Latest Headlines | Tagged Abbott, ABT, AEterna Zentaris, AEZS, BG Medicine, BGMD, BIIB, Biogen Idec, Boston Scientific, BSX, CELG, Celgene, Merck, MRK, NASDAQ:AEZS, NASDAQ:BGMD, NASDAQ:BIIB, NASDAQ:CELG, NYSE:ABT, NYSE:BSX, NYSE:MRK, NYSE:PFE, NYSE:UNH, PFE, Pfizer, UNH, UnitedHealth | Comments Off

PAREXEL International (NASDAQ:PRXL) Inks $72 Million Deal to Acquire Liquent – PRXL, CVD, HLF, ARNA, AEZS, PFE, MRK, JNJ

Posted on December 31, 2012 by Geoff Noir

PAREXEL International Corporation (NASDAQ:PRXL) reported that it had purchased all outstanding shares of Liquent, Inc from Marlin Equity Partners on December 21 for almost $72 million.

Biopharmaceutical services company PAREXEL International has revised up its service revenue outlook for the …

Posted in Latest Headlines, Services | Tagged AEterna Zentaris, AEZS, arena, ARNA, Covance, CVD, Herbalife, HLF, JNJ, Johnson, Merck, MRK, NASDAQ:AEZS, NASDAQ:ARNA, NASDAQ:PRXL, NYSE:CVD, NYSE:HLF, NYSE:JNJ, NYSE:MRK, NYSE:PFE, Parexel International, PFE, Pfizer, PRXL | Comments Off

AEterna Zentaris (NASDAQ:AEZS) Stock Hikes after FDA Deal – AEZS, MRK, SPPI, NVS

Posted on December 29, 2012 by Geoff Noir

AEterna Zentaris Inc’s (USA) (NASDAQ:AEZS) stock moved up almost 20% on Friday after the Canadian drug manufacturer reported that it has agreed with United States rules on the design of a late-stage inquiry for its endometrial cancer treatment.

The Canadian …

Posted in Healthcare, Latest Headlines | Tagged AEterna Zentaris, AEZS, Merck, MRK, NASDAQ:AEZS, NASDAQ:SPPI, Novartis AG, NVS, NYSE:MRK, NYSE:NVS, Spectrum Pharmaceuticals, SPPI | Comments Off

Healthcare Sector Lands in Green zone; Biosante (BPAX) to Merge with ANI Pharmaceuticals while HMS (HMSY) Cuts Outlook – BPAX, HMSY, PFE, AEZS, ESMC, NUVA

Posted on October 5, 2012 by Thomas Vedder

Healthcare sector responded positively on Thursday’s trading session and sector hiked +0.69%. If we look at the top movers of the sector so AEterna Zentaris Inc. (USA) (NASDAQ:AEZS) and Escalon Medical Corp. (NASDAQ:ESMC) were major percentage gainers while major percentage …

Posted in Healthcare, Latest Headlines | Tagged AEterna Zentaris, AEZS, Biosante, BPAX, Escalon Medical, ESMC, HMS, HMSY, NASDAQ:AEZS, NASDAQ:BPAX, NASDAQ:ESMC, NASDAQ:HMSY, NASDAQ:NUVA, NUVA, NuVasive, NYSE:PFE, PFE, Pfizer | Comments Off

Novavax (NASDAQ:NVAX) Shares Surges on Healthy Results- NVAX, KERX, DNDN, ARNA, BPAX, AEZS, CTIC

Posted on May 7, 2012 by Geoff Noir

Novavax Inc (NASDAQ:NVAX) shares climbed 2.22 percent to $1.38 following the firm posted Q1 results. Net loss was $7.3 million or $0.06 a share evaluated with net loss of $7.5 million or $0.07 a share in the Q1 of 2011. …

Posted in Latest Headlines | Tagged AEterna Zentaris, AEZS, Arena Pharmaceuticals, ARNA, BioSante Pharmaceuticals, BPAX, Cell Therapeutics, CTIC, Dendreon, DNDN, KERX, Keryx Biopharmaceuticals, NASDAQ:AEZS, NASDAQ:ARNA, NASDAQ:BPAX, NASDAQ:CTIC, NASDAQ:DNDN, NASDAQ:KERX, NASDAQ:NVAX, Novavax, NVAX | Comments Off

Healthcare Giant GlaxoSmithKline (NYSE:GSK) Bid on Human Genome Sciences- HGSI, GSK, HGSI, DNDN, ARNA, KERX, BPAX, VVUS, AEZS

Posted on April 20, 2012 by Geoff Noir

Biotech drug maker Human Genome Sciences (NASDAQ:HGSI) has refused an unwanted $2.59 billion acquisition bid by GlaxoSmithKline (NYSE:GSK), the British pharmaceutical giant that spent almost 20 years helping the smaller firms bring its first drug to market.

Rockville, Md.-based …

Posted in Healthcare, Latest Headlines | Tagged AEterna Zentaris, AEZS, Arena Pharmaceuticals, ARNA, BioSante Pharmaceuticals, BPAX, Dendreon, DNDN, HGSI, Human Genome Sciences, KERX, Keryx Biopharmaceuticals, NASDAQ:AEZS, NASDAQ:ARNA, NASDAQ:BPAX, NASDAQ:DNDN, NASDAQ:HGSI, NASDAQ:KERX, NASDAQ:VVUS, Vivus, VVUS | Comments Off

Stock Market Quotes and Streaming Charts - QuoteDaddy.com Level 2 Stock Quotes from Quote Daddy on Vimeo.

blogs

Lorimer Wilson Analyst

Dian L. Chu "EconMatters"

Paul Ebeling Trading News

Warren Bevan Precious Metals

eStocksDaily.com ("ESD") is not an investment advisory service, nor a registered investment advisor or broker-dealer and does not purport to tell or suggest which securities customers should buy or sell for themselves. The employees or affiliates of ESD may hold positions in the stocks or industries discussed here. You understand and acknowledge that there is a very high degree of risk involved in trading securities. ESD, the authors, the publisher, and all affiliates of ESD assume no responsibility or liability for your trading and investment results. Factual statements on the ESD's website, or in its publications, are made as of the date stated and are subject to change without notice. For ESD full disclaimer and disclosure go to our disclaimer page.It should not be assumed that the methods, techniques, or indicators presented in these products will be profitable or that they will not result in losses. Past results of any individual trader or trading system published by ESD are not indicative of future returns by that trader or system, and are not indicative of future returns which be realized by you. In addition, the indicators, strategies, columns, articles and all other features of ESD's products (collectively, the "Information") are provided for informational and educational purposes only and should not be construed as investment advice. Examples presented on ESD's website are for educational purposes only. Such set-ups are not solicitations of any order to buy or sell. Accordingly, you should not rely solely on the Information in making any investment. Rather, you should use the Information only as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments. You should always check with your licensed financial advisor and tax advisor to determine the suitability of any investment.